echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lancet subjournal: Characteristics of circulating tumor DNA variation in aggressive breast lobular carcinoma

    Lancet subjournal: Characteristics of circulating tumor DNA variation in aggressive breast lobular carcinoma

    • Last Update: 2022-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Currently, there is limited
    data on molecular differences in circulating tumor DNA (ctDNA) in patients with invasive breast lobular carcinoma (ILC).
    The study analyzed data from patients with metastatic breast cancer who underwent ctDNA testing to assess genomic differences
    in patients with ILC, invasive ductal carcinoma (IDC), and mixed tissue types.

    The researchers retrospectively analyzed data from 980 breast cancer patients with detailed clinical data (121 ILC, 972 IDC, and 62 mixed tissue types) and compared the single nucleotide variant (SNV), copy number variation (CNV) and oncogenic signaling pathway
    in the tissue samples.


    Variant profiles of ctDNA in ILC, IDC, and mixed-tissue patients

    ILC was significantly associated
    with negative HR+ HER2 and low HER2 expression.
    Patients with ILC had a higher SNV (p<0.
    05)
    compared to patients with IDC or mixed tissue type.
    In multivariate analyses, HR+ HER2-negative ILC was significantly associated
    with mutations in the CDH1 (OR 9.
    4), ERBB2 (OR 3.
    6), and PTEN (OR 2.
    5) genes.
    In the mixed tissue patient cohort, no CDH1 mutation
    was detected.
    Gene mutations in the PI3K signaling pathway are more common in patients with ILC (OR 1.
    76).

    In a separate cohort of nearly 7,000 patients with metastatic breast cancer, CDH1 co-mutated
    significantly with targetable variants (PIK3CA, ERBB2) and endocrine resistance-associated mutations (ARID1A, NF1, RB1, ESR1, FGFR2).

    In conclusion, the evaluation of ctDNA in this study revealed the differences in pathogenic variants and carcinogenic signaling pathways of breast cancer in different tissue types, which has guiding significance
    for histological classification and precision medicine treatment.

    Original source:

    Andrew A.
    Davis, et al.
    Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer.
    eBioMedicine.
    November 01, 2022.
    https://doi.
    org/10.
    1016/j.
    ebiom.
    2022.
    104316

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.